Korro Bio submits ethics review request in Australia for KRRO-121 first-in-human trial

• Korro Bio submitted an application to Alfred Health Human Ethics Committee in Australia to start a first-in-human Phase 1/2 trial of KRRO-121.
• KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide being developed for hyperammonemia in patients with urea cycle disorders.
• The study aims to evaluate safety, tolerability, pharmacokinetics, and early activity in healthy volunteers and participants with urea cycle disorders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-356877), on August 19, 2026, and is solely responsible for the information contained therein.